Esperion CFO Richard Bartram to step down effective April 8, 2022

Esperion Therapeutics, Inc.

CFO, Principal Financial Officer and Principal Accounting Officer Richard B. Bartram departing.
Departure effective April 8, 2022; no successor named in filing.
Decision not due to any disagreement with company operations, policies or practices.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Richard B. Bartram

Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer

ESPR · Esperion Therapeutics, Inc.

Effective: 2022-04-08
Filed: March 15, 2022, 7:59 PM ET

On March 15, 2022, Esperion Therapeutics, Inc. (the “Company”) announced that Richard B. Bartram was stepping down from his positions as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer of the Company, effective as of April 8, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Richard B. Bartram departed as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer at Esperion Therapeutics, Inc..

Action: stepping down
Role: Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer

Exact text from the filing

On March 15, 2022, Esperion Therapeutics, Inc. (the “Company”) announced that Richard B. Bartram was stepping down from his positions as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer of the Company, effective as of April 8, 2022.

View on SEC.gov

Esperion Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-033912

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.